{"version":"1.0","type":"link","title":"Anthracycline-Free Neoadjuvant Pertuzumab-Trastuzumab-Taxane in Patients with HER2-Positive Early Breast Cancer: Hormone Receptor Status as a Key Determinant of Pathological Complete Response.","author_name":"Irelli A 외","author_url":"https://prs-insight.online/author/Irelli%20A","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/80260","thumbnail_width":1200,"thumbnail_height":630}